Pre-Series A · Biotech
SEGNOS secures pre-Series A equity funding
The Japanese diagnostics-materials company received investment from the TUAT1 fund managed by BP Capital.
SEGNOS announced a pre-Series A financing on October 22 through a third-party allotment of shares to TUAT1号投資事業有限責任組合. The amount was not disclosed.
The funding will support research and development in healthcare testing and in-vitro diagnostics. The company develops Therma-Max magnetic nanoparticles and related detection methods, while continuing its technology partnership with existing shareholder JNC.
Masashi Tsuda is joining as director and COO, with responsibility for management, strategy and operations.
Funding history
Pre-Series A · This roundUndisclosed